Chronic inflammatory demyelinating polyneuropathy (CIDP) results in disability through immune-mediated nerve injury, which can lead to irreversible deficits after the inflammatory component of CIDP is ...

Just a few months into a new launch in chronic inflammatory demyelinating polyneuropathy (CIDP), agrenx’s Vyvgart is already making headway in the rare disease space, just one of the long-term growth ...

A blockbuster Argenx therapy now has an additional FDA approval as a treatment for a rare autoimmune disorder affecting nerves, marking the first new treatment for this condition in decades and a new ...

PHOENIX — Subcutaneous efgartigimod PH20 SC shows efficacy and tolerability in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), providing a convenient alternative to ...

Please provide your email address to receive an email when new articles are posted on . Reasons for misdiagnosis or delayed diagnosis for CIDP are complex and include multiple factors. The FDA ...

The US Food and Drug Administration (FDA) has approved the combination of efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo, argenx) for treatment of adults with chronic inflammatory ...

Argenx is urging patients to “Live Vyvidly.” The biotech put the message out in a direct-to-consumer TV ad that paints Vyvgart Hytrulo as a drug that can help people with chronic inflammatory ...

CEO Tim Van Hauwermeiren emphasized 2024 as a "phenomenal year," highlighted by expanding the reach of VYVGART to over 10,000 patients globally across three approved indications. He noted the ...

(RTTNews) - Takeda Pharmaceutical Co. Ltd. (TAK) announced Tuesday favorable long-term data from the Phase 3 ADVANCE-CIDP 3 clinical trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) diagnoses are frequently missed or delayed and standard treatments -- intravenous immunoglobulin (IVIG), steroids, and plasma exchange -- are ...